Neurogene Inc. Files 8-K for Disclosure and Exhibits

TL;DR

Neurogene filed an 8-K on 4/22 for disclosures and exhibits.

AI Summary

Neurogene Inc. filed an 8-K on April 22, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is located at 535 W 24th Street, 5th Floor, New York, NY 10011.

Why It Matters

This filing indicates Neurogene Inc. is providing updated information to the SEC, which could include material updates relevant to investors.

Risk Assessment

Risk Level: low — This is a routine filing for disclosures and exhibits, not indicating any immediate negative or positive event.

Key Players & Entities

• Neurogene Inc. (company) — Registrant
• Neoleukin Therapeutics, Inc. (company) — Former company name
• April 22, 2024 (date) — Date of report
• 535 W 24th Street, 5th Floor, New York, NY 10011 (location) — Principal executive offices address

FAQ

Key Financial Figures

• $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market

Filing Documents

• ngne-20240422.htm (8-K) — 27KB
• ngne_asgctcurtainraiserxve.htm (EX-99.1) — 17KB
• image_0a.jpg (GRAPHIC) — 3KB
• 0001404644-24-000029.txt ( ) — 178KB
• ngne-20240422.xsd (EX-101.SCH) — 2KB
• ngne-20240422_lab.xml (EX-101.LAB) — 22KB
• ngne-20240422_pre.xml (EX-101.PRE) — 13KB
• ngne-20240422_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 22, 2024, Neurogene Inc. (the "Company") issued a press release announcing the presentation of initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome at the American Society for Gene and Cell Therapy Annual Meeting demonstrating that its NGN-401 gene therapy candidate has been generally well tolerated, and that there have been no treatment-emergent or procedure-related serious adverse events or signs of MeCP2 overexpression-related toxicity observed in any patient, including a patient with a mild variant predicted to result in residual MeCP2 function. A copy of the press release announcing this presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated April 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: April 22, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR